Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods:...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/11/1543 |
| _version_ | 1797467297626980352 |
|---|---|
| author | Alessandro Rizzo Massimiliano Salati Giorgio Frega Valeria Merz Francesco Caputo Alessandro Di Federico Andrea Palloni Riccardo Carloni Angela Dalia Ricci Gennaro Gadaleta-Caldarola Carlo Messina Andrea Spallanzani Fabio Gelsomino Stefania Benatti Gabriele Luppi Davide Melisi Massimo Dominici Giovanni Brandi |
| author_facet | Alessandro Rizzo Massimiliano Salati Giorgio Frega Valeria Merz Francesco Caputo Alessandro Di Federico Andrea Palloni Riccardo Carloni Angela Dalia Ricci Gennaro Gadaleta-Caldarola Carlo Messina Andrea Spallanzani Fabio Gelsomino Stefania Benatti Gabriele Luppi Davide Melisi Massimo Dominici Giovanni Brandi |
| author_sort | Alessandro Rizzo |
| collection | DOAJ |
| description | Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods: Institutional registries across three academic medical centers were retrospectively reviewed. The Kaplan–Meier methods were used to estimate survival, and the log-rank test was used to make comparisons. Results: A total of 190 BTC patients treated with 2L were identified and included in the analysis. Among them, 52 (27.3%) were aged ≥ 70 years (range 70–87 years). No statistically significant differences in both median overall survival (mOS) and median progression-free survival (mPFS) were recorded between the elderly and younger patients. Absolute lymphocyte count < 1000/mmc (<i>p</i> < 0.001) and albumin level < 3 g/dL (<i>p</i> < 0.001) were independently associated with worse prognoses. Conclusions: The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset. |
| first_indexed | 2024-03-09T18:51:38Z |
| format | Article |
| id | doaj.art-21706d9457d3468996d4a95259512694 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T18:51:38Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-21706d9457d3468996d4a952595126942023-11-24T05:46:32ZengMDPI AGMedicina1010-660X1648-91442022-10-015811154310.3390/medicina58111543Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World StudyAlessandro Rizzo0Massimiliano Salati1Giorgio Frega2Valeria Merz3Francesco Caputo4Alessandro Di Federico5Andrea Palloni6Riccardo Carloni7Angela Dalia Ricci8Gennaro Gadaleta-Caldarola9Carlo Messina10Andrea Spallanzani11Fabio Gelsomino12Stefania Benatti13Gabriele Luppi14Davide Melisi15Massimo Dominici16Giovanni Brandi17Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyPhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, 41121 Modena, ItalyOsteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, ItalyDepartment of Medical Oncology, Santa Chiara Hospital, 35127 Trento, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, 40138 Bologna, ItalyMedical Oncology Unit, National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital, 70013 Castellana Grotte, ItalyMedical Oncology Unit, ‘Mons. R. Dimiccoli’ Hospital, Barletta (BT), Azienda Sanitaria Locale Barletta, 76121 Barletta, ItalyDepartment of Medical Oncology, Santa Chiara Hospital, 35127 Trento, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyDigestive Molecular Clinical Oncology Research Unit, University of Verona, 37129 Verona, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, 40138 Bologna, ItalyObjectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods: Institutional registries across three academic medical centers were retrospectively reviewed. The Kaplan–Meier methods were used to estimate survival, and the log-rank test was used to make comparisons. Results: A total of 190 BTC patients treated with 2L were identified and included in the analysis. Among them, 52 (27.3%) were aged ≥ 70 years (range 70–87 years). No statistically significant differences in both median overall survival (mOS) and median progression-free survival (mPFS) were recorded between the elderly and younger patients. Absolute lymphocyte count < 1000/mmc (<i>p</i> < 0.001) and albumin level < 3 g/dL (<i>p</i> < 0.001) were independently associated with worse prognoses. Conclusions: The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset.https://www.mdpi.com/1648-9144/58/11/1543biliary tract cancercholangiocarcinomasecond-linechemotherapyelderly |
| spellingShingle | Alessandro Rizzo Massimiliano Salati Giorgio Frega Valeria Merz Francesco Caputo Alessandro Di Federico Andrea Palloni Riccardo Carloni Angela Dalia Ricci Gennaro Gadaleta-Caldarola Carlo Messina Andrea Spallanzani Fabio Gelsomino Stefania Benatti Gabriele Luppi Davide Melisi Massimo Dominici Giovanni Brandi Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study Medicina biliary tract cancer cholangiocarcinoma second-line chemotherapy elderly |
| title | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study |
| title_full | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study |
| title_fullStr | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study |
| title_full_unstemmed | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study |
| title_short | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study |
| title_sort | second line chemotherapy in elderly patients with advanced biliary tract cancer a multicenter real world study |
| topic | biliary tract cancer cholangiocarcinoma second-line chemotherapy elderly |
| url | https://www.mdpi.com/1648-9144/58/11/1543 |
| work_keys_str_mv | AT alessandrorizzo secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT massimilianosalati secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT giorgiofrega secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT valeriamerz secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT francescocaputo secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT alessandrodifederico secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT andreapalloni secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT riccardocarloni secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT angeladaliaricci secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT gennarogadaletacaldarola secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT carlomessina secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT andreaspallanzani secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT fabiogelsomino secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT stefaniabenatti secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT gabrieleluppi secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT davidemelisi secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT massimodominici secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy AT giovannibrandi secondlinechemotherapyinelderlypatientswithadvancedbiliarytractcanceramulticenterrealworldstudy |